CoChat

A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis

Open access

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.

Abstract

Rheumatoid arthritis (RA) is strongly associated with the human leukocyte antigen (HLA)-DRB1 locus that possesses the shared susceptibility epitope (SE) and the citrullination of self-antigens. We show how citrullinated aggrecan and vimentin epitopes bind to HLA-DRB1*04:01/04. Citrulline was accommodated within the electropositive P4 pocket of HLA-DRB1*04:01/04, whereas the electronegative P4 pocket of the RA-resistant HLA-DRB1*04:02 allomorph interacted with arginine or citrulline-containing epitopes. Peptide elution studies revealed P4 arginine–containing peptides from HLA-DRB1*04:02, but not from HLA-DRB1*04:01/04. Citrullination altered protease susceptibility of vimentin, thereby generating self-epitopes that are presented to T cells in HLA-DRB1*04:01+ individuals. Using HLA-II tetramers, we observed citrullinated vimentin- and aggrecan-specific CD4+ T cells in the peripheral blood of HLA-DRB1*04:01+ RA-affected and healthy individuals. In RA patients, autoreactive T cell numbers correlated with disease activity and were deficient in regulatory T cells relative to healthy individuals. These findings reshape our understanding of the association between citrullination, the HLA-DRB1 locus, and T cell autoreactivity in RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20131241

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. HLA-DRB1*04:01 in complex with Vimentin-71Cit66-78. (a) Polymorphic residues involved in susceptibility to RA. The peptide-binding groove of an HLA-DR molecule is shown in cartoon representation with the α-chain colored in green and the β-chain colored in pink. Residues Val11β, His13β, Lys71β, and Ala74β are represented as sticks and correspond to the residues present in HLA-DR401, the HLA with the highest risk associated with RA. (b) Sequence alignment of the three HLA-DRB1*04 alleles used in this study showing amino acid polymorphisms. “-” indicates residue conserved with that of HLA-DRB1*04:01:01. Val11β, His13β are conserved in all three alleles (not depicted). (c) HLA-DRB1*04:01 in complex with vimentin-71Cit66-78. The vimentin-71Cit66-78 peptide is bound in the peptide-binding groove, with carbons colored in yellow, nitrogens colored in blue, and oxygens colored in red. The α and β chains are shown in cartoon representation, and colored in green and pink, respectively. (d) Side view of the bound vimentin-71Cit66-78 peptide. The peptide’s 2Fo-Fc electron density map is shown in blue and contoured to 1 σ, showing unambiguous density for the peptide. Peptide residues are labeled and numbered, with Citrulline71 occupying the P4 pocket.
Figure 1. HLA-DRB1*04:01 in complex with Vimentin-71Cit66-78. (a) Polymorphic residues involved in susceptibility to RA. The peptide-binding groove of an HLA-DR molecule is shown in cartoon representation with the α-chain colored in green and the β-chain colored in pink. Residues Val11β, His13β, Lys71β, and Ala74β are represented as sticks and correspond to the residues present in HLA-DR401, the HLA with the highest risk associated with RA. (b) Sequence alignment of the three HLA-DRB1*04 alleles used in this study showing amino acid polymorphisms. “-” indicates residue conserved with that of HLA-DRB1*04:01:01. Val11β, His13β are conserved in all three alleles (not depicted). (c) HLA-DRB1*04:01 in complex with vimentin-71Cit66-78. The vimentin-71Cit66-78 peptide is bound in the peptide-binding groove, with carbons colored in yellow, nitrogens colored in blue, and oxygens colored in red. The α and β chains are shown in cartoon representation, and colored in green and pink, respectively. (d) Side view of the bound vimentin-71Cit66-78 peptide. The peptide’s 2Fo-Fc electron density map is shown in blue and contoured to 1 σ, showing unambiguous density for the peptide. Peptide residues are labeled and numbered, with Citrulline71 occupying the P4 pocket.CC BY-NC-SA · PubMed Central
Figure 2. Side view of epitopes bound to HLA-DR4. (a) HLA-DRB1*04:01 bound to vimentin-64Cit59-71. (b) HLA-DRB1*04:01 bound to vimentin-64-69-71Cit59-71. (c) HLA-DRB1*04:01 bound to aggrecan-93-95Cit89-103. (d) HLA-DRB1*04:04 bound to vimentin-71Cit59-71. (e) HLA-DRB1*04:02 bound to vimentin-71Cit66-78. (f) HLA-DRB1*04:02 bound to Vimentin66-78. The peptide’s 2Fo-Fc electron density map is shown in blue and contoured to 1 σ. Peptide residues are labeled and numbered.
Figure 2. Side view of epitopes bound to HLA-DR4. (a) HLA-DRB1*04:01 bound to vimentin-64Cit59-71. (b) HLA-DRB1*04:01 bound to vimentin-64-69-71Cit59-71. (c) HLA-DRB1*04:01 bound to aggrecan-93-95Cit89-103. (d) HLA-DRB1*04:04 bound to vimentin-71Cit59-71. (e) HLA-DRB1*04:02 bound to vimentin-71Cit66-78. (f) HLA-DRB1*04:02 bound to Vimentin66-78. The peptide’s 2Fo-Fc electron density map is shown in blue and contoured to 1 σ. Peptide residues are labeled and numbered.CC BY-NC-SA · PubMed Central
Figure 3. Interactions with citrulline in the P4 pocket of HLA-DRB1*04:01 and HLA-DRB1*04:04. (a) Vimentin-71Cit66-78 colored in yellow, (b) vimentin-64Cit59-71 colored in pink, (c) vimentin-64-69-71Cit59-71 colored in green, and (d) aggrecan-93-95Cit89-103 (colored in blue, bound to HLA-DRB1 *04:01). Residues from the β chain important for contacts with the P4 citrulline are represented as sticks. (e) Vimentin-71Cit66-78 colored in teal bound to HLA-DRB1*04:04.
Figure 3. Interactions with citrulline in the P4 pocket of HLA-DRB1*04:01 and HLA-DRB1*04:04. (a) Vimentin-71Cit66-78 colored in yellow, (b) vimentin-64Cit59-71 colored in pink, (c) vimentin-64-69-71Cit59-71 colored in green, and (d) aggrecan-93-95Cit89-103 (colored in blue, bound to HLA-DRB1 *04:01). Residues from the β chain important for contacts with the P4 citrulline are represented as sticks. (e) Vimentin-71Cit66-78 colored in teal bound to HLA-DRB1*04:04.CC BY-NC-SA · PubMed Central
Figure 4. Comparison of the interactions between citrulline and arginine in the P4 pocket of HLA-DRB1*04:02. (a) Vimentin-71Cit66-78 colored in green; (b) Vimentin66-78 colored in purple. The solvent-accessible electrostatic potential was calculated for panel c HLA-DRB1*04:01 and (d) HLA-DRB1*04:02 bound to vimentin-71Cit66-78. Electrostatic calculations were performed using APBS (±12 kT/e).
Figure 4. Comparison of the interactions between citrulline and arginine in the P4 pocket of HLA-DRB1*04:02. (a) Vimentin-71Cit66-78 colored in green; (b) Vimentin66-78 colored in purple. The solvent-accessible electrostatic potential was calculated for panel c HLA-DRB1*04:01 and (d) HLA-DRB1*04:02 bound to vimentin-71Cit66-78. Electrostatic calculations were performed using APBS (±12 kT/e).CC BY-NC-SA · PubMed Central
Figure 5. HLA-DRB1*04 binding motifs and protease sensitivity of citrullinated epitopes. (a) HLA Binding motifs of DRB1*04:01, DRB1*04:02 and DRB1*04:04 were generated from immunoaffinity purified allotypes isolated from T2-DRB1*04:01, 04:02 and 04:04 cells expressing DM. Each HLA DR allotype was affinity purified, and bound peptides were isolated and analyzed by Liquid chromatography–mass spectrometry (LC-MS/MS). To generate peptide-binding motifs, the minimal core sequences found within nested sets were extracted and the resulting list of peptides aligned and visualized using Icelogo. Positively associated residues (P > 0.05) at each relative position are shown above the x-axis and negatively associated residues are shown below. Residues height is proportionate to prevalence, with residues shown in pink having infinite height reflecting absolute presence or absence at that position in the bound peptides. (b) Citrullination alters cleavage of vimentin by Cathepsin L. Recombinant human vimentin was citrullinated in vitro, and the Cathepsin L digestion patterns of native and citrullinated vimentin were observed by LC-MS/MS. Observed cleavages are highlighted by arrows in the region of vimentin-spanning residues 51–81. The amount of selected peptides (as determined by area under the curve quantitation for extracted ion chromatograms) from this region that span the immunogenic 59–71 region of vimentin are shown as a function of digestion time (1, 5, 3, and 60 min digests).
Figure 5. HLA-DRB1*04 binding motifs and protease sensitivity of citrullinated epitopes. (a) HLA Binding motifs of DRB1*04:01, DRB1*04:02 and DRB1*04:04 were generated from immunoaffinity purified allotypes isolated from T2-DRB1*04:01, 04:02 and 04:04 cells expressing DM. Each HLA DR allotype was affinity purified, and bound peptides were isolated and analyzed by Liquid chromatography–mass spectrometry (LC-MS/MS). To generate peptide-binding motifs, the minimal core sequences found within nested sets were extracted and the resulting list of peptides aligned and visualized using Icelogo. Positively associated residues (P > 0.05) at each relative position are shown above the x-axis and negatively associated residues are shown below. Residues height is proportionate to prevalence, with residues shown in pink having infinite height reflecting absolute presence or absence at that position in the bound peptides. (b) Citrullination alters cleavage of vimentin by Cathepsin L. Recombinant human vimentin was citrullinated in vitro, and the Cathepsin L digestion patterns of native and citrullinated vimentin were observed by LC-MS/MS. Observed cleavages are highlighted by arrows in the region of vimentin-spanning residues 51–81. The amount of selected peptides (as determined by area under the curve quantitation for extracted ion chromatograms) from this region that span the immunogenic 59–71 region of vimentin are shown as a function of digestion time (1, 5, 3, and 60 min digests).CC BY-NC-SA · PubMed Central
Figure 6. CD4+tetramer+ T cells circulate in RA patients and healthy controls. (a) PBMC from a representative HLA-DRB1*04:01+ RA patient were stained with PE-labeled HLA-DRB1*04:01-HA306-318 tetramer and Brilliant Violet 421 (BV)-labeled HLA-DRB1*04:01-vimentin-64Cit59-71 tetramer and FITC-labeled anti-CD11c, CD14, CD16, and CD19 and APC/Cy7-labeled anti-CD4, and then analyzed by flow cytometry, setting gates on FITC−CD4+ cells based on PE- and BV-fluorescence minus one (FMO) staining. PBMCs from 9 HLA-DRB1*04:01+ RA patients (RA, filled circles) and 4 healthy controls (HC, empty circles) were stained with AQUA live dead discriminator, PE-labeled HLA-DRB1*04:01-HA306-318, -vimentin-64Cit59-71, or -aggrecan-93-95Cit89-103 tetramers, Alexa Fluor 488 Foxp3, PerCP/Cy5.5-CD14, Pacific blue-CD45RO, APC-CD28, APC/Cy7-CD4, PE/Cy7-CD25, and count beads were added. Either CD4+CD14−tetramer+ or total CD4+ T cells were gated and the frequency of CD4+CD14−tetramer+ or total CD4+CD14− cells/ml blood was calculated (b). The number of HLA-DRB1*04:01-vimentin-64Cit59-71–specific T cells was plotted relative to the four variable disease activity score (DAS4vCRP) of each RA patient (c). MFI of tetramer+ T cells (d), percentage of CD4+CD45RO−CD25+Foxp3+ resting T reg cells (e), CD4+CD45RO+CD25hiFoxp3+ activated T reg cells (f), CD4+CD45RO−CD25−Foxp3− naive T cells (g) or CD4+CD45RO+CD25−Foxp3− effector/memory T cells (h) of RA patients (columns 1, 3, 5, and 7) and healthy controls (columns 2, 4, 6, and 8) is shown for each or tetramer+ population (columns 1–6) and for total PB CD4+ T cells (columns 7 and 8). *, P < 0.05; **, P < 0.01, using the Mann-Whitney test to compare RA patients and healthy controls. The number of PB HLA-DRB1*04:01-vimentin-64Cit59-71–specific T cells were correlated with disease activity score in RA patients (Spearman r = 0.76; P < 0.05).
Figure 6. CD4+tetramer+ T cells circulate in RA patients and healthy controls. (a) PBMC from a representative HLA-DRB1*04:01+ RA patient were stained with PE-labeled HLA-DRB1*04:01-HA306-318 tetramer and Brilliant Violet 421 (BV)-labeled HLA-DRB1*04:01-vimentin-64Cit59-71 tetramer and FITC-labeled anti-CD11c, CD14, CD16, and CD19 and APC/Cy7-labeled anti-CD4, and then analyzed by flow cytometry, setting gates on FITC−CD4+ cells based on PE- and BV-fluorescence minus one (FMO) staining. PBMCs from 9 HLA-DRB1*04:01+ RA patients (RA, filled circles) and 4 healthy controls (HC, empty circles) were stained with AQUA live dead discriminator, PE-labeled HLA-DRB1*04:01-HA306-318, -vimentin-64Cit59-71, or -aggrecan-93-95Cit89-103 tetramers, Alexa Fluor 488 Foxp3, PerCP/Cy5.5-CD14, Pacific blue-CD45RO, APC-CD28, APC/Cy7-CD4, PE/Cy7-CD25, and count beads were added. Either CD4+CD14−tetramer+ or total CD4+ T cells were gated and the frequency of CD4+CD14−tetramer+ or total CD4+CD14− cells/ml blood was calculated (b). The number of HLA-DRB1*04:01-vimentin-64Cit59-71–specific T cells was plotted relative to the four variable disease activity score (DAS4vCRP) of each RA patient (c). MFI of tetramer+ T cells (d), percentage of CD4+CD45RO−CD25+Foxp3+ resting T reg cells (e), CD4+CD45RO+CD25hiFoxp3+ activated T reg cells (f), CD4+CD45RO−CD25−Foxp3− naive T cells (g) or CD4+CD45RO+CD25−Foxp3− effector/memory T cells (h) of RA patients (columns 1, 3, 5, and 7) and healthy controls (columns 2, 4, 6, and 8) is shown for each or tetramer+ population (columns 1–6) and for total PB CD4+ T cells (columns 7 and 8). *, P < 0.05; **, P < 0.01, using the Mann-Whitney test to compare RA patients and healthy controls. The number of PB HLA-DRB1*04:01-vimentin-64Cit59-71–specific T cells were correlated with disease activity score in RA patients (Spearman r = 0.76; P < 0.05).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Pettit, 2000, Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates, Arthritis Rheum., 43, 791, 10.1002/1529-0131(200004)43:4<791::aid-anr9>3.0.co;2-e · doi:10.1002/1529-0131(200004)43:4<791::aid-anr9>3.0.co;2-e

Cited by

See all 505

Metadata

Authors
Scally, S. W., Petersen, J., Law, S. C., Dudek, N. L., Nel, H. J., Loh, K. L., Wijeyewickrema, L. C., Eckle, S. B. G., van Heemst, J., Pike, R. N., McCluskey, J., Toes, R. E., La Gruta, N. L., Purcell, A. W., Reid, H. H., Thomas, R., & Rossjohn, J.
Affiliations
  • Monash University (AU)
  • Translational Research Institute (AU)
  • The University of Melbourne (AU)
  • Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, Netherlands 4
  • Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia 3
Corresponding author
  • Purcell, Anthony W.
  • Reid, Hugh H.
  • Thomas, Ranjeny
  • Rossjohn, Jamie
Venue
Journal of Experimental Medicine
Published
2013-11-04
Volume
210
Issue
12
Pages
2569-2582
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2146707828
Cited by
429
References
59
Citations by year
2026: 22 · 2025: 22 · 2024: 27 · 2023: 42 · 2022: 25 · 2021: 31 · 2020: 33 · 2019: 41 · 2018: 36 · 2017: 41 · 2016: 48 · 2015: 35 · 2014: 25 · 2013: 1
FWCI
29.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders
National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, HLA-DRB1, citrullination, citrullinated vimentin, HLA-DRB1*0401, peptide binding, autoreactive T cells, CD4+ T cells, regulatory T cells, disease activity, autoantigens
MeSH terms
Amino Acid Sequence, Animals, Epitopes, Arthritis, Rheumatoid, Autoantigens, Citrulline, Humans, Mice, Transgenic, Models, Molecular, Molecular Sequence Data, Polymorphism, Genetic, Vimentin, CD4-Positive T-Lymphocytes, HLA-DR4 Antigen, Antigen Presentation, Mice, Aggrecans, Genetic Association Studies, HLA-DR beta-Chains, HLA-DRB1 Chains

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.